Q2B25 Paris | Anders Broo, Executive Director, Head of Data Science & Modelling, AstraZeneca @QCWare
Q2B25 Paris | Anders Broo, Executive Director, Head of Data Science & Modelling, AstraZeneca  @QCWare
Uploaded October 2025 | Updated September 2026, 2 weeks ago
Quantum Computing Use Cases in the Drug Discovery and Development:

Recent advances in quantum computing hardware and software have heightened expectations for a paradigm shift in our ability to model every stage of drug discovery and development. The prospect of tackling exponentially complex problems is especially compelling. In this talk, I will present some of the work done at AstraZeneca, where we are exploring how quantum computing can be harnessed to address some of the most challenging issues in the field.

q2b.qcware.com
Q2B25 Paris | Anders Broo, Executive Director, Head of Data Science & Modelling, AstraZenecaQ2B25 Paris | Dorit  Dor, Co founder, QBeat VenturesQ2B26 Tokyo | Remy Notermans, Director of Strategic Planning, Atom ComputingQ2B25 Silicon Valley | Is Near Term Quantum Advantage Possible? How So? - SAS PanelQ2B26 Tokyo | Joe Spencer, Director, GQIQ2B26 Tokyo | Ryo Sakurai and Naoki Mitsumoto, DENSO CORPORATIONQ2B26 Tokyo | Dr. Michael J. Biercuk, CEO & Founder, Q-CTRLQ2B25 Silicon Valley | Mark Jackson, Senior Quantum Evangelist, QuantinuumQ2B25 Paris | Pharmaceutical PanelQ2B26 Tokyo | Masako Yamada, Senior Director Applications and Mei Maruo, Senior Physicist, IonQQ2B25 Paris | Aaron Trowbridge, CEO, HarmoniqsQ2B25 Silicon Valley | Quantum Technologies: Innovation and Investment Panel
QC Ware |

Q2B25 Paris | Anders Broo, Executive Director, Head of Data Science & Modelling, AstraZeneca

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER